[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2011019326A3 - Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité - Google Patents

Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité Download PDF

Info

Publication number
WO2011019326A3
WO2011019326A3 PCT/TR2010/000127 TR2010000127W WO2011019326A3 WO 2011019326 A3 WO2011019326 A3 WO 2011019326A3 TR 2010000127 W TR2010000127 W TR 2010000127W WO 2011019326 A3 WO2011019326 A3 WO 2011019326A3
Authority
WO
WIPO (PCT)
Prior art keywords
solubility
stability
enchancing
pharmaceutical formulation
therapeutic agent
Prior art date
Application number
PCT/TR2010/000127
Other languages
English (en)
Other versions
WO2011019326A2 (fr
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Priority to EP10782065A priority Critical patent/EP2448919A2/fr
Publication of WO2011019326A2 publication Critical patent/WO2011019326A2/fr
Publication of WO2011019326A3 publication Critical patent/WO2011019326A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des formulations pharmaceutiques comprenant l'association d'un agent thérapeutique présentant un problème de solubilité et d'un agent thérapeutique présentant un problème de stabilité. L'invention concerne également des méthodes de préparation de ces formulations, et l'utilisation de telles formulations.
PCT/TR2010/000127 2009-07-02 2010-06-25 Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité WO2011019326A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10782065A EP2448919A2 (fr) 2009-07-02 2010-06-25 Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR200905148 2009-07-02
TR2009/5148 2009-07-02

Publications (2)

Publication Number Publication Date
WO2011019326A2 WO2011019326A2 (fr) 2011-02-17
WO2011019326A3 true WO2011019326A3 (fr) 2011-04-28

Family

ID=43501056

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2010/000127 WO2011019326A2 (fr) 2009-07-02 2010-06-25 Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité

Country Status (2)

Country Link
EP (1) EP2448919A2 (fr)
WO (1) WO2011019326A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2566465A2 (fr) * 2010-05-04 2013-03-13 Mahmut Bilgic Formulations stables de rosuvastatine
SI2844233T1 (sl) 2012-05-01 2020-08-31 Althera Life Sciences, Llc Peroralna tableta, sestavljena iz fiksne kombinacije rosuvastatina in ezetimiba za zdravljenje hiperlipidemije in bolezni srca in ožilja
US10376470B2 (en) 2012-05-01 2019-08-13 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
HU231036B1 (hu) * 2013-09-30 2019-12-30 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Koleszterin bioszintézis gátló hatóanyagot és koleszterin abszorpciót gátló hatóanyagot tartalmazó kombinációs gyógyszerkészítmény
TWI586380B (zh) * 2013-12-18 2017-06-11 夢製藥公司 包含ＨＭＧ－ＣｏＡ還原酶抑制劑及膽固醇吸收抑制劑之醫藥組合製劑
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
KR101977785B1 (ko) * 2014-06-25 2019-05-14 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법
EP3243506A1 (fr) 2016-05-09 2017-11-15 Adamed sp. z o.o. Composition pharmaceutique
CZ2016539A3 (cs) 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy
CZ2016538A3 (cs) 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky
GR1009727B (el) * 2018-11-28 2020-04-14 Elpen Αε Φαρμακευτικη Βιομηχανια Μονολιθικη σταθερη φαρμακοτεχνικη μορφη ταχειας αποδεσμευσης εζετιμιμπης και ροσουβαστατινης
CN117137876A (zh) * 2023-08-07 2023-12-01 福建东瑞制药有限公司 瑞舒伐他汀钙片及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010993A1 (fr) * 2002-07-26 2004-02-05 Merck Sharp & Dohme Limited Compositions comprenant un inhibiteur de l'absorption du cholesterol, un inhibiteur de la hmg-coa reductase et un stabilisateur
WO2007003365A1 (fr) * 2005-07-06 2007-01-11 Krka Composition pharmaceutique comprenant de la simvastatine et de l'ézétimibe
WO2008101723A2 (fr) * 2007-02-23 2008-08-28 Krka Composition pharmaceutique comprenant un inhibiteur d'absorption du cholestérol
WO2009024889A2 (fr) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Composition pharmaceutique comprenant un inhibiteur de réductase hmg-coa et un ézétimibe

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
TW200719916A (en) 2005-04-12 2007-06-01 Psivida Inc HMGCoA reductase inhibitor combinations and uses thereof
WO2006134604A1 (fr) 2005-06-15 2006-12-21 Hetero Drugs Limited Composition combinant un inhibiteur d’absorption du cholestérol et un inhibiteur de la 3-hydroxy-3-méthylglutaryl-coenzyme a (hmg-coa) réductase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004010993A1 (fr) * 2002-07-26 2004-02-05 Merck Sharp & Dohme Limited Compositions comprenant un inhibiteur de l'absorption du cholesterol, un inhibiteur de la hmg-coa reductase et un stabilisateur
WO2007003365A1 (fr) * 2005-07-06 2007-01-11 Krka Composition pharmaceutique comprenant de la simvastatine et de l'ézétimibe
WO2008101723A2 (fr) * 2007-02-23 2008-08-28 Krka Composition pharmaceutique comprenant un inhibiteur d'absorption du cholestérol
WO2009024889A2 (fr) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Composition pharmaceutique comprenant un inhibiteur de réductase hmg-coa et un ézétimibe

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVIDSON M H ET AL: "Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 40, no. 12, 18 December 2002 (2002-12-18), pages 2125 - 2134, XP001155704, ISSN: 0735-1097, DOI: DOI:10.1016/S0735-1097(02)02610-4 *
GAGNE C ET AL: "EFFICACY AND SAFETY OF EZETIMIBE COADMINISTERED WITH ATORVASTATIN OR SIMVASTATIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 105, no. 21, 28 May 2002 (2002-05-28), pages 2469 - 2475, XP001132086, ISSN: 0009-7322, DOI: DOI:10.1161/01.CIR.0000018744.58460.62 *

Also Published As

Publication number Publication date
WO2011019326A2 (fr) 2011-02-17
EP2448919A2 (fr) 2012-05-09

Similar Documents

Publication Publication Date Title
WO2011019326A3 (fr) Formulation pharmaceutique permettant d'augmenter la solubilité et la stabilité
IL268756B (en) Piperazine-2,5-dione derivatives, pharmaceutical preparations containing them and their use for the preparation of medicines
WO2012021715A3 (fr) Formulations stables de linaclotide
IL239639A0 (en) A modified spiropyrido {1,2-a} pyrazine derivative and its medicinal use as an HIV integrase inhibitor
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL233677A (en) Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition
IL206952A (en) History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines
EP2605698A4 (fr) Photopléthysmographie de site central, administration de médicament et sécurité
IL213019A (en) Derivatives 1-Azo-3-Terroyl-Azoline, Pharmaceutical Preparations Containing and Using Them
WO2012020097A3 (fr) Utilisation de liants pour la fabrication de formulations stables à l'entreposage
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2010021607A3 (fr) Préparation pharmaceutique
PT2655375E (pt) Derivados de pirimidinona, sua preparação e sua utilização farmacêutica
WO2011017502A3 (fr) Formulations comprenant du linaclotide
WO2011141488A3 (fr) Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone
WO2011076842A3 (fr) Préparation aérosol pour copd (bronchopneumopathie chronique obstructive)
WO2011002422A3 (fr) Formulation pharmaceutique améliorant la solubilité
WO2012030914A8 (fr) Dérivés de 4-azolylaminoquinazoline et leurs méthodes d'utilisation
WO2011142731A3 (fr) Formulations comprenant une céphalosporine et un acide clavulanique de troisième génération
WO2011076840A3 (fr) Préparation aérosol pour bronchopneumopathie chronique obstructive
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
EP2409685A3 (fr) Formulations de prasugrel à désintégration orale
WO2011125006A3 (fr) Nouveaux composés sultame
WO2011002424A3 (fr) Préparation pharmaceutique améliorant la solubilité et la stabilité
WO2012064306A3 (fr) Formulations effervescentes de rosuvastatine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10782065

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010782065

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010782065

Country of ref document: EP